UA127858U - METHOD OF DIAGNOSTICS OF ATHEROSCLEROSIS DEVELOPMENT - Google Patents

Abstract

A method of diagnosing the development of atherosclerosis includes clinical examination, studies of low and high density lipoprotein cholesterol levels, arteriography, determination of eNOS T786C gene polymorphism in serum, endothelin, folic acid, CISR, EWS, IL-6 content. With homozygous carrier 786-SS, endothelin levels> 10 ng / ml, folic acid <6 ng / ml, SICP <102 ng / ml, SRP> 6 mg / l, IL-6> 10 ng / l diagnose the development of atherosclerosis.

Description

The proposed method of diagnosing the development of atherosclerosis belongs to medicine, in particular to therapy and rheumatology. It is prescribed and can be used in the treatment and examination of patients.

Ways of diagnosing the development of atherosclerosis are known. These include determination of low- and high-density lipoprotein cholesterol levels, arteriography (AN Okorokov.

Diagnosis of diseases of internal organs. - Vol. 6 - pp. 75-85).

However, the known method is not effective enough and does not allow diagnosing the development of atherosclerosis even at the onset of the disease. Accordingly, there is no possibility to prevent atherosclerosis.

The basis of a useful model is the task of developing a method that would allow diagnosing the onset of atherosclerosis at an early stage.

The task is solved by the fact that, along with the study of low and high-density lipoprotein cholesterol levels, the polymorphism of the nitric oxide synthase gene (EMO5 T786C), the content of endothelin, folic acid, C-terminal propeptide of type I collagen (SISR) is determined in the patient's blood serum by arteriography. C-reactive protein (CRP), interleukin 6 (IL-6). With homozygous carrier 786-SS, levels of endothelin 210 ng/ml, folic acid "6 ng/ml,

SISR "102 ng/ml, SRP "6 mg/l, IL-6 "10 ng/l diagnose the development of atherosclerosis.

Application of the method. During hospitalization, the patient is examined, low- and high-density lipoprotein cholesterol levels are examined, and arteriography is performed. In the blood serum of the patient, the polymorphism of the eMmo5 1786C gene is determined, and the content of endothelin, folic acid, SISR, SRP, and IL-6 is determined by the immunoenzymatic method. With homozygous carrier 786-SS, levels of endothelin 210 ng/ml, folic acid "b ng/ml, SSRI "102 ng/ml, SRP "6 mg/l, IL-6 "10 ng/l, the development of atherosclerosis is diagnosed.

A specific example of using the method.

Patient S., 58 years old, was hospitalized in the clinic with a diagnosis of rheumatoid arthritis.

Examined Low and high density lipoprotein cholesterol levels were studied. Arteriography was performed. No signs of atherosclerosis were detected. The polymorphism of the eEeMO5 17860 gene was determined in the blood serum. The content of endothelin, folic acid,

SISR, SRP, IL-6. Homozygous carrier 786-SS was established. Levels of endothelin - 17 ng/ml, folic acid - 3.9 ng/ml, SICR - 82 ng/ml, SRP - 14 mg/l, IL-6 - 19 ng/l. The development of atherosclerosis was diagnosed. Arteriographic confirmation of the diagnosis was obtained only after 12 months.

Thus, the proposed method makes it possible to establish a diagnosis at the early stages of the development of the process.

Claims (1)

USEFUL MODEL FORMULA A method of diagnosing the development of atherosclerosis, which includes a clinical examination, a study of low and high-density lipoprotein cholesterol levels, arteriography, which is distinguished by that determine in blood serum the polymorphism of the eMmo5 T786C gene, the content of endothelin, folic acid, SISR, SRP, IL-6 and in homozygous carriers of 786-SS, levels of endothelin 210 ng/ml, folic acid "6 ng/ml, SISR "102 ng /ml, SRP »6 mg/l, IL-6 »10 ng/l diagnose the development of atherosclerosis.